It is biotech stocks like Cubist Pharmaceuticals (Nasdaq:CBST) that keep investors coming back into a sector that is arguably more famous for spectacular failures than reliable success. While Cubist stock has not reclaimed the highs of the 2000-2001 era, the company has nevertheless ridden the success of its antibiotic Cubicin to become a near 10-bagger from the lows of late 2002. The question for investors now, though, is whether the company can find another Cubicin and keep the investor enthusiasm healthy.
TUTORIAL: Forex Trading 101

A Solid, But Not Special, Second Quarter
Cubist reported sales growth of 5% for the second quarter, fueled by 9% growth from the company's core drug, Cubicin. Although Cubicin sales were a bit stronger than analysts were generally expecting, overall revenue was basically in line with expectations. Margin performance was likewise unspectacular in either direction - the company saw some gross margin erosion (due in part to larger sales discounts), but adjusted operating income growth tracked revenue.

The Need to Go Beyond Cubicin
At the time of its introduction in 2003, Cubicin was a big deal - one of the first really new antibiotics to hit the market in years, and one with a very different mechanism of action than the standard therapies. It was also something of an improbable success - the drug was originally discovered and developed by Eli Lilly (NYSE:LLY) but ultimately abandoned and sold to Cubist.

Cubicin has made a niche for itself as a second-line (and, in some cases, first-line) therapy for serious infections like MRSA (Methicillin-resistant Staphylococcus aureus). That said, Cubicin still competes with cheaper alternatives like generic vancomycin and branded drugs like Forest Labs' (NYSE:FRX) Teflaro and Pfizer's (NYSE:PFE) Zyvox.

While Cubist got a significant win for itself when it negotiated a settlement with Teva (Nasdaq:TEVA) that will keep Cubicin generics off the market until 2017 or 2018, the clock is still ticking.

The Pipeline
One of the leading concerns with Cubist is the relatively thin pipeline of two drugs. CXA-201 is going to head into phase three studies for urinary tract infections and complicated intraabdominal infections, and it could be a valuable gram-negative antibiotic, but it may be worth only about one-third of Cubicin in terms of market value for the stock. Even if CXA-201 shows strong efficacy in certain lung infections, the value would not rise to that of a replacement for Cubicin.

Cubist is also waiting to make a go/no-go decision on a phase three trial for CB,315 in C.diff - another serious infection with increasing issues of resistance to available drugs. Phase two results were encouraging, but do not suggest category-killer potential. Complicating matters is that clinical results for 315 seem fairly similar to those of Optimer's (Nasdaq:OPTR) Dificid - a drug that Cubist recently agreed to co-promote.

Worries About Competition and Acquisition
On one hand, Cubist benefits from the fact that antibiotics just are not a very popular area of research for large pharmaceutical companies. True, companies like AstraZeneca (NYSE:AZN) and Sanofi (NYSE:SNY) are working on some compounds, as well as smaller biotechs like Achaogen. The problem, though, is that antibiotics are difficult to develop (compounds that are good at killing living things like bacteria tend to have side effects) and the markets are not that large - antibiotic resistance is a problem, but many infections can still be handled by cheap generics, and that limits market and pricing potential.

Some shareholders also seem to be troubled by the possibility that Cubist will pursue acquisitions to fill out its pipeline and/or give its salesforce more product to sell. This concern largely comes down to one of horizon - investors who want to hold Cubist for a while should be encouraged by pipeline-filling deals (assuming reasonable valuations), while investors holding in the hopes that Cubist itself gets bought out will likely view these deals as unnecessarily risky and disruptive to deal prospects.

The Bottom Line
Cubicin is a good drug, but Cubist looks fairly priced today. An acquisition could certainly change the company's pipeline value, but it is hard to see many near-term events that would fuel a major rise in the stock price apart from an outright sale of the company to a larger drug company. (In a volatile market, domestic investing can be risky. Many investors choose to look overseas for diversification - but that strategy comes with its own risks. To learn more, see The Risks Of Investing In Emerging Markets.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Personal Finance

    Protect Your Home From Medicaid Liens

    Plan ahead for long-term care needs to protect your home and your estate.
  2. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  3. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  4. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  7. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  8. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
  9. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  10. Mutual Funds & ETFs

    ETF Analysis: Schwab US Broad Market

    Take an in-depth look at the Schwab U.S. Broad Market ETF, an incredibly low-cost fund based on a wide selection of the U.S. equity market.
RELATED TERMS
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  5. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
  6. BHD (Berhad)

    The suffix Bhd. is an abbreviation of a Malay word "berhad," ...
RELATED FAQS
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  4. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  5. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
  6. What happens to the shares of stock purchased in a tender offer?

    The shares of stock purchased in a tender offer become the property of the purchaser. From that point forward, the purchaser, ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!